Androgenetic alopecia (AGA) is the most common cause of hair loss, it has been reported as high as 67% in men over 50 years of age and 37% in postmenopausal women. About 50% of men and 13% of women start to experience AGA hair loss between puberty to middle age.

In male AGA hair starts thinning from the frontal temples to the scalp and crown. In female AGA the frontal hairline is preserved but there is diffuse thinning to the scalp. Shorter, finer, miniaturised (vellus) hairs from a briefer growth (anagen) cycle are characteristic of AGA.

Current treatment for hair loss include Minoxidil (a vasodilator) and Finasteride (an androgen blocker whose Side effects have been well reported. In some cases at a certain age a follicular unit extraction (FUE) or follicular unit transplantation (FUT) surgery can help mask AGA.

Platelet rich plasma (PRP) for AGA has been shown to offer no more benefit than the clinical saline (salt water) placebo used in a randomised double-blind clinical trial. Micro-needling, a wound healing cascade effector, better explained any beneficial outcome for patients. PRP is not regenerative.

Whilst an androgen (testosterone) by-product called dihydrotestosterone (DHT) stimulates the growth (anagen) cycle of hair, paradoxically it is found in high levels in what’s termed as ‘androgen sensitive’ areas of the scalp that are prone to AGA thinning and balding.

A thinning of the subcutaneous (fat and connective) tissue and loss of adequate blood supply in areas of the scalp induces cellular stresses; and seems to be casual of hair follicle stem cells going out of cycle, the complex progression of which is male and female AGA.

Ironically, increased signalling by distressed hair follicle cells for growth would induce more DHT; further disrupting the out of cycle cellular environment by prematurely calling for hair growth cycles to restart, lessening the hair size each time as is characteristic of AGA.

Its apparent why drug and surgery treatments can often mitigate AGA. However, these are not scalp regenerative strategies that seek to address the apparent cause of AGA. Ideally, regenerative strategies should be considered at early signs of AGA; not as the last resort after all else has failed, and damage is maximising.

Below is a case of AGA reversal achieved in three sessions over a 12 month period using our combined scalp and hair follicle treatment approach with AdMSC based therapy. A year prior to AdMSC based treatment, this individual paid for multiple PRP sessions with no apparent benefit for his ongoing hair loss.

Protect and enhance your hair with a regenerative-based treatment.


This approach is designed to protect and enhance the thick-coverage terminal hairs.

It may be worth considering a course of AdMSC based treatments as a alternative to hair transplantation surgery. Hair follicles (entire individual organs) removed by such transplantation from the back of the head do not regrow, and only a limited number of follicles can be removed without loss of hair coverage.

AdMSC based treatments can also be used as a supportive therapy to FUE and FUT. Such stem cells based treatments are helpful to these transplanted hair follicles ultimately flourishing, or in resolving with potential fibrosis (scarring) in the case of FUT.

AdMSC based treatments also provide an opportunity for a base of vellus and terminal hairs to regenerate from the dormant follicles in the hair transplant area and suppliment the same, to provide more coverage than otherwise might be possible.